ArticleScientific reports2026
Bioactive metabolites from endophytic Fusarium equiseti isolated from Hyoscyamus muticus mitigate cadmium toxicity in biological models.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cadmium is a hazardous metal that induces oxidative stress, hepato-renal dysfunction, and metabolic disturbances. This study investigated the protective potential of bioactive secondary metabolites extracted from endophytic Fusarium equiseti (FE) against cadmium-induced toxicity. Gas chromatography- Mass Spectrometry (GC-MS) profiling revealed 17 compounds dominated by esters (67%) and fatty acids (26%). The major constituents were 9,12-Octadecadienoic acid (Z,Z) (10.21%), and Oleic acid (8.13%). In vitro-FE exhibited dose dependent antioxidant activity (IC50 = 145.91µ g/ml in DPPH assay) and broad-spectrum antimicrobial efficacy, producing inhibition zones up to 46 mm against E. coli. Anti- inflammatory evaluation showed hemolysis inhibition rising from 3.1% (100 µg/mL) to 55.9% (1000 µg/ml). Furthermore, the MTT assay revealed that the FE exhibited moderate cytotoxicity against HeLa and PC3 (IC50 values of 194.15 µg/ml and 162.88 µg/ml, respectively) cancer cell lines, while showing a lower toxicity toward normal WI38 cells (IC50 of 237.26 µg/ml; Selectivity Index up to 1.46). These metabolites are suggested to be the key contributors to the extract's antioxidant and antimicrobial activities. In vivo, twenty Wistar rats were randomly assigned to four sets (n = 5 per set): (1) Control; (2) CdCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.